BackgroundTherapeutic inhibition of PCSK9 protects against coronary artery disease (CAD) and ischemic stroke (IS). The impact on other diseases remains less well characterized.MethodsWe created a genetic risk score (GRS) for PCSK9 using four single nucleotide polymorphisms (SNPs) at or near the PCSK9 locus known to impact lower LDL-Cholesterol (LDL-C): rs11583680, rs11591147, rs2479409, and rs11206510. We then used our GRS to calculate weighted odds ratios reflecting the impact of a genetically determined 10 mg/dL decrease in LDL-C on several pre-specified phenotypes including CAD, IS, peripheral artery disease (PAD), abdominal aortic aneurysm (AAA), type 2 diabetes, dementia, chronic obstructive pulmonary disease, and cancer. Finally, we u...
Detecting genetic risk factors for better targeting of statin administration can further enhance the...
International audiencePro-protein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator...
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a protein involved in LDL-cholesterol ...
Aims: PCSK9 genetic variants that have large effects on low density lipoprotein cholesterol (LDL-C) ...
Importance: Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase levels o...
We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...
Background We characterised the phenotypic consequence of genetic variation at the P...
Introduction: PCSK9 inhibitors lower low-density lipoprotein (LDL) cholesterol and are efficacious ...
International audienceBackground PCSK9 (Proprotein convertase subtilisin/kexin type 9) binds low-den...
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolism,...
PCSK9 loss-of-function (LOF) variants allow for the examination of the effects of lifetime reduced l...
Detecting genetic risk factors for better targeting of statin administration can further enhance the...
International audiencePro-protein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator...
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a protein involved in LDL-cholesterol ...
Aims: PCSK9 genetic variants that have large effects on low density lipoprotein cholesterol (LDL-C) ...
Importance: Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase levels o...
We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...
Background We characterised the phenotypic consequence of genetic variation at the P...
Introduction: PCSK9 inhibitors lower low-density lipoprotein (LDL) cholesterol and are efficacious ...
International audienceBackground PCSK9 (Proprotein convertase subtilisin/kexin type 9) binds low-den...
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolism,...
PCSK9 loss-of-function (LOF) variants allow for the examination of the effects of lifetime reduced l...
Detecting genetic risk factors for better targeting of statin administration can further enhance the...
International audiencePro-protein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator...
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a protein involved in LDL-cholesterol ...